NCT07010523View on ClinicalTrials.gov

Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

NARecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

October 14, 2026

Study Completion Date

October 14, 2027

Conditions
Mesothelin-positive Advanced Malignant Solid Tumors
Interventions
BIOLOGICAL

Anti-mesothelin CAR-T cells

D0: 0.1×10\^6/Kg\~1.0×10\^6/Kg; cells will be infused intravenously.

DRUG

Fludarabine

D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.

DRUG

Cyclophosphamide

D-7 to D-3: Cyclophosphamide (300 mg/m\^2/day) will be administered intravenously for 5 days.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

UTC Therapeutics Inc.

INDUSTRY

lead

Zhejiang University

OTHER